# VectorY Therapeutics

> Amsterdam clinical-stage biotech developing one-time vectorized antibody treatments for ALS and other neurodegenerative diseases.

## Why it is interesting

Its AAV-delivered intracellular antibody approach could sustain antibody production in the central nervous system, but human safety and disease-modifying efficacy remain to be established. A November 2026 €74.5M financing package includes €30M EIB convertible debt, so it is not an all-equity Series B.

## Profile

- **Latest funding:** Mixed financing package (not all equity; no Series B designation) — €74.5M combined financing INCLUDING €30M EIB convertible loan and €7M Invest-NL equity; other component allocations not fully disclosed (November 11, 2026)
- **Latest known valuation:** Not publicly disclosed
- **Total disclosed equity funding:** Not publicly disclosed
- **Stage:** series-a
- **Status:** private
- **Industries:** N/A
- **Coverage:** full
- **Last updated:** 2026-11-13
- **Latest funding investors:** European Investment Bank, Invest-NL, Angelini Ventures, Forbion, EQT Life Sciences, Insight Partners

## Key facts

- November 11, 2026 financing package €74.5M combines equity and EIB convertible loan; the latter is €30M, not equity.
- Invest-NL discloses €7M equity contribution; no total-equity split or valuation confirmed.
- PIONEER-ALS open-label Phase 1/2 studies safety and exploratory efficacy; 36-participant expansion announced September 2026.

## Funding history

- Mixed financing package (not all equity; no Series B designation) · €74.5M combined financing INCLUDING €30M EIB convertible loan and €7M Invest-NL equity; other component allocations not fully disclosed · November 11, 2026
  Source: https://www.vectorytx.com/news/vectory-expands-pioneer-als-phase-12-clinical-trial-size-4jeae
- Series A · €129M equity financing (2023) · November 13, 2023
  Source: https://www.vectorytx.com/news/vectory-raises-129-million-138-million-series-a-financing-to-advance-vectorized-antibody-programs-in-neurodegenerative-diseases

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** November 13, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/vectory-therapeutics